-
Cycloheximide for RNA–Protein Causality Studies
2026-09-12
Cycloheximide is a protein biosynthesis inhibitor that can sharpen causal analysis of RNA stability, translation, and protein turnover. This guide connects translational control with the FTO–MTUS1/ATIP1 axis while emphasizing assay design, controls, and interpretation limits.
-
SEMA3E, β-Catenin, and Beige Adipocyte Thermogenesis
2026-09-11
A 2026 mouse study identifies SEMA3E as a positive regulator of beige adipocyte differentiation and non-shivering thermogenesis, linking its activity to mitochondrial oxidative phosphorylation and β-catenin signaling. The work combines genetic perturbation, adipose transplantation, AAV-mediated knockdown, transcriptomics, and mitochondrial respiration assays to establish a mechanistic framework for studying adipose tissue plasticity.
-
Golgi-Tracker Green for Live Golgi Imaging
2026-09-11
Golgi-Tracker Green is a BODIPY FL-labeled C5-ceramide probe for selective Golgi labeling in live cells. Its reported photostability, solvent compatibility, and live-cell restriction support Golgi apparatus imaging, lipid transport pathway visualization, and sphingolipid metabolism analysis.
-
Indomethacin Workflows for Inflammation Research
2026-09-10
Indomethacin supports controlled dissection of cyclooxygenase activity, PPAR-linked transcription, lipid handling, and membrane organization in cell-based assays. This practical guide connects dose design and assay controls with the FXR–KLF11 findings reported in contrast-induced kidney injury research, while clearly separating established evidence from exploratory use.
-
Quaternization Reprograms Lung-Targeted mRNA Delivery
2026-09-10
The 2024 Theranostics study shows that N-quaternization of a lipid-like compound can convert systemic mRNA delivery from spleen accumulation to highly selective lung targeting. Its findings identify head-group chemistry as a relatively simple design variable for directing pulmonary delivery, while also highlighting the importance of cell-specific uptake, storage stability, and translation readouts.
-
Serine/Glycine-Free Diet and PD-L1 Lactylation
2026-09-09
A 2024 Cell Metabolism study shows that a serine/glycine-free diet can suppress colorectal cancer growth and increase cytotoxic T-cell accumulation, while also enabling immune evasion through PD-L1 lactylation. The work links dietary metabolism to checkpoint regulation and provides early clinical evidence that the intervention is feasible and safe, although combination with immunotherapy requires further validation.
-
Nebivolol Hydrochloride as an Assay Control
2026-09-09
Nebivolol hydrochloride is more than a selective β1-adrenoceptor antagonist: it can help researchers separate receptor-mediated cardiovascular biology from unrelated mTOR effects. This article translates a yeast-based mTOR screening study into practical assay design, controls, and interpretation strategies.
-
EZ Cap™ EGFP mRNA: Practical Workflow Guide
2026-09-08
EZ Cap™ EGFP mRNA provides a Cap 1 EGFP reporter mRNA input for evaluating delivery and expression in research systems. It is suitable for controlled reporter workflows, but the supplied dossier does not establish a universal dose, cell type, readout window, or performance outcome.
-
Nebivolol hydrochloride for β1 Signaling Assays
2026-09-08
Nebivolol hydrochloride combines nanomolar β1-adrenoceptor selectivity with a useful negative result in a sensitized yeast mTOR screen. This makes it valuable for separating cardiovascular receptor biology from TOR-pathway effects while improving assay controls, dosing logic, and troubleshooting.
-
Esflurbiprofen and SERT-nNOS in Rapid Antidepressant Action
2026-09-07
The reference study identifies esflurbiprofen as a preclinical fast-onset antidepressant candidate that disrupts the SERT-nNOS complex in the dorsal raphe nucleus. Its combination of mBRET screening, stress-model pharmacology, and rs-fMRI links a molecular interaction to serotonergic circuit and behavioral changes, while also defining important limits for translation beyond mice.
-
p21 mRNA-LNPs for Local Bladder Cancer Therapy
2026-09-07
The reference study presents intravesical delivery of chemically modified p21 mRNA in lipid nanoparticles as a localized tumor-suppressor replacement strategy for bladder cancer. Its preclinical evidence connects restored nuclear p21 expression with cell-cycle inhibition, DNA-damage signaling, apoptosis, bladder-localized protein expression, and reduced tumor growth in an orthotopic mouse model.
-
Pertussis toxin Workflows for Immune Signaling
2026-09-05
Use Pertussis toxin as a controlled cAMP-pathway perturbation tool for dendritic-cell phenotyping, signaling time courses, and comparative immune assays. This workflow also shows how to connect toxin-driven observations with TREM2–ERK/p38 research without confusing active toxin with a detoxified vaccine antigen.
-
Aligned Ce6 Silk Fibroin Films for Infected Wounds
2026-09-04
The reference study developed an aligned silk fibroin electrospun film with covalently conjugated Chlorin e6 for light-triggered antibacterial treatment of S. aureus-infected wounds. Its main innovation is the integration of photodynamic bacterial killing, anisotropic cell guidance, blood compatibility, and late-stage macrophage M2 polarization within one biomaterial platform.
-
SCH772984: Selective ERK1/2 Inhibitor Workflow
2026-09-04
SCH772984 provides a direct way to interrogate ERK1/2 signaling in mutation-driven cancer models, from short-term target engagement to clonogenic and xenograft studies. This workflow connects MAPK/ERK pathway inhibition with practical assays for proliferation, radioresistance, and ferroptosis while distinguishing established evidence from testable extensions.
-
Imipenem Workflows for Antibacterial Research
2026-09-03
Build more informative antibacterial assays with Imipenem by linking PBP-mediated killing, susceptibility kinetics, and immune readouts. This guide translates product properties into practical workflows for resistance studies, phagocytosis experiments, and sepsis animal model design while separating evidence-backed findings from assay recommendations.